| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1034050S |
| P356 | DOI | 10.1371/JOURNAL.PONE.0134050 |
| P932 | PMC publication ID | 4517903 |
| P698 | PubMed publication ID | 26218526 |
| P5875 | ResearchGate publication ID | 280539066 |
| P50 | author | Martin Schwarzer | Q57045425 |
| P2093 | author name string | Hana Kozakova | |
| Dagmar Srutkova | |||
| Irma Schabussova | |||
| Tomas Hudcovic | |||
| Zuzana Zakostelska | |||
| Bohuslav Rittich | |||
| Alena Spanova | |||
| Vladimir Drab | |||
| P2860 | cites work | Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics | Q21131205 |
| Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment | Q21562212 | ||
| Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 | ||
| A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease | Q22251291 | ||
| Translatability of helminth therapy in inflammatory bowel diseases | Q22252437 | ||
| Probiotics for maintenance of remission in Crohn's disease | Q24244110 | ||
| Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial | Q24685494 | ||
| The role of macrophages and dendritic cells in the initiation of inflammation in IBD | Q26827408 | ||
| Dendritic cell subsets in the intestinal lamina propria: ontogeny and function | Q26997819 | ||
| Dextran sodium sulphate colitis mouse model: traps and tricks | Q27001084 | ||
| Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease | Q27860821 | ||
| Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease | Q28201834 | ||
| Gut flora in health and disease | Q28209082 | ||
| Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic | Q28241661 | ||
| Intestinal barrier function: molecular regulation and disease pathogenesis | Q28250081 | ||
| Crohn's disease | Q28273481 | ||
| Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy | Q28727435 | ||
| Interleukin-10-deficient mice develop chronic enterocolitis | Q29547881 | ||
| Microbial influences in inflammatory bowel diseases | Q29614264 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy | Q33194695 | ||
| Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity | Q33309955 | ||
| Microbiomic analysis of the bifidobacterial population in the human distal gut. | Q33419297 | ||
| Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy | Q33503647 | ||
| The microbiome in inflammatory bowel disease: current status and the future ahead | Q33664898 | ||
| Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders | Q33719638 | ||
| Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease | Q73285248 | ||
| The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice | Q77775758 | ||
| Comparative effects of six probiotic strains on immune function in vitro | Q82348866 | ||
| Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide | Q83798992 | ||
| Inflammatory bowel disease | Q84081963 | ||
| Inhibitory Effects of Bifidobacterium longum on Experimental Ulcerative Colitis Induced in Mice by Synthetic Dextran Sulfate Sodium | Q44438716 | ||
| A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice | Q44753508 | ||
| Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
| Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. | Q46935325 | ||
| Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. | Q49073992 | ||
| Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis | Q50454240 | ||
| Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. | Q50470100 | ||
| Microbiota in pediatric inflammatory bowel disease. | Q54432000 | ||
| Evaluation of amplified ribosomal DNA restriction analysis (ARDRA) and species-specific PCR for identification of Bifidobacterium species. | Q54621776 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Intestinal permeability and the prediction of relapse in Crohn's disease | Q72220492 | ||
| The treatment-naive microbiome in new-onset Crohn's disease | Q33762817 | ||
| Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria | Q33787825 | ||
| Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats | Q33797774 | ||
| Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers | Q33985774 | ||
| Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization. | Q34158110 | ||
| Efficiency of PCR-based methods in discriminating Bifidobacterium longum ssp. longum and Bifidobacterium longum ssp. infantis strains of human origin | Q34200434 | ||
| The immunology of mucosal models of inflammation | Q34542265 | ||
| A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease | Q34588311 | ||
| A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis | Q34628053 | ||
| Current and emerging drugs for the treatment of inflammatory bowel disease | Q34883210 | ||
| New targets for mucosal healing and therapy in inflammatory bowel diseases | Q35003977 | ||
| Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? | Q35195891 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. | Q36580437 | ||
| Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. | Q36669765 | ||
| Regulation of intestinal microbiota by the NLR protein family | Q36685310 | ||
| Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis | Q37098695 | ||
| Exploring the diversity of the bifidobacterial population in the human intestinal tract | Q37127701 | ||
| Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults | Q37240389 | ||
| Potentially probiotic bacteria induce efficient maturation but differential cytokine production in human monocyte-derived dendritic cells. | Q37352177 | ||
| Epithelial tight junctions in intestinal inflammation | Q37524296 | ||
| Immunosuppressive therapies for inflammatory bowel disease | Q37660661 | ||
| The gut microbiota in IBD. | Q38036078 | ||
| Animal models of inflammatory bowel diseases: illuminating the pathogenesis of colitis, ileitis and cancer | Q38053026 | ||
| Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. | Q38076962 | ||
| Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities. | Q38115600 | ||
| Bifidobacteria and humans: our special friends, from ecological to genomics perspectives | Q38130478 | ||
| Control of intestinal inflammation by interleukin-10. | Q38227342 | ||
| Transmission of intestinal Bifidobacterium longum subsp. longum strains from mother to infant, determined by multilocus sequencing typing and amplified fragment length polymorphism. | Q38628343 | ||
| Distinct Bifidobacterium strains drive different immune responses in vitro. | Q39910194 | ||
| Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair | Q40211588 | ||
| Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. | Q40328326 | ||
| Neonatal colonization of germ-free mice with Bifidobacterium longum prevents allergic sensitization to major birch pollen allergen Bet v 1. | Q42246982 | ||
| Clinicopathologic study of dextran sulfate sodium experimental murine colitis. | Q42506472 | ||
| Chemically induced mouse models of intestinal inflammation | Q42510602 | ||
| Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? | Q42636819 | ||
| Modulation of human dendritic cell phenotype and function by probiotic bacteria | Q43004747 | ||
| Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier | Q43132701 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Bifidobacterium longum | Q4904768 |
| colitis | Q2453464 | ||
| P304 | page(s) | e0134050 | |
| P577 | publication date | 2015-07-28 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner | |
| P478 | volume | 10 |
| Q47163293 | A New Proposal for the Pathogenic Mechanism of Non-Coeliac/Non-Allergic Gluten/Wheat Sensitivity: Piecing Together the Puzzle of Recent Scientific Evidence |
| Q39127400 | Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases |
| Q46237028 | Bifidobacteria and Their Molecular Communication with the Immune System. |
| Q38775839 | Brachyspira hyodysenteriae and B. pilosicoli Proteins Recognized by Sera of Challenged Pigs. |
| Q26748440 | Bugging inflammation: role of the gut microbiota |
| Q28817192 | Can probiotics modulate human disease by impacting intestinal barrier function? |
| Q39020374 | Capacity of lactic acid bacteria in immunity enhancement and cancer prevention. |
| Q90603920 | Case Report: Acute Amebic Colitis Triggered by Colonoscopy: Exacerbation of Asymptomatic Chronic Infection with Entamoeba histolytica Accompanied by Dysbiosis |
| Q98290847 | Cyclic nigerosylnigerose ameliorates DSS-induced colitis with restoration of goblet cell number and increase in IgA reactivity against gut microbiota in mice |
| Q48186544 | Development of a potential probiotic yoghurt using selected anti-inflammatory lactic acid bacteria for prevention of colitis and carcinogenesis in mice |
| Q42358507 | Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis |
| Q55497507 | Dietary Polysaccharide from Enteromorpha Clathrata Modulates Gut Microbiota and Promotes the Growth of Akkermansia muciniphila, Bifidobacterium spp. and Lactobacillus spp. |
| Q55506746 | Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. |
| Q64061620 | Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology |
| Q40785098 | Genome Structure of the Symbiont Bifidobacterium pseudocatenulatum CECT 7765 and Gene Expression Profiling in Response to Lactulose-Derived Oligosaccharides. |
| Q64252284 | Germ-Free Mice Exhibit Mast Cells With Impaired Functionality and Gut Homing and Do Not Develop Food Allergy |
| Q37293230 | Immunoreactive Proteins of Bifidobacterium longum ssp. longum CCM 7952 and Bifidobacterium longum ssp. longum CCDM 372 Identified by Gnotobiotic Mono-Colonized Mice Sera, Immune Rabbit Sera and Non-immune Human Sera. |
| Q64880411 | Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis |
| Q64095187 | Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission |
| Q92796101 | Lactobacillus fermentum species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota |
| Q64084688 | Loading ceftriaxone, vancomycin, and Bifidobacteria bifidum TMC3115 to neonatal mice could differently and consequently affect intestinal microbiota and immunity in adulthood |
| Q47105416 | Probiotic Enhanced Intestinal Immunity in Broilers against Subclinical Necrotic Enteritis. |
| Q55027051 | Probiotic Species in the Modulation of Gut Microbiota: An Overview. |
| Q46279792 | Probiotic strains and mechanistic insights for the treatment of type 2 diabetes. |
| Q48511475 | Probiotics in Gut-Bone Signaling. |
| Q26740603 | Proteinaceous Molecules Mediating Bifidobacterium-Host Interactions |
| Q37662501 | Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients |
| Q92110453 | Strain-Specific Anti-inflammatory Properties of Two Akkermansia muciniphila Strains on Chronic Colitis in Mice |
| Q64911296 | Synbiotic Supplementation Containing Whole Plant Sugar Cane Fibre and Probiotic Spores Potentiates Protective Synergistic Effects in Mouse Model of IBD. |
| Q89749252 | Synbiotic supplementation with prebiotic green banana resistant starch and probiotic Bacillus coagulans spores ameliorates gut inflammation in mouse model of inflammatory bowel diseases |
| Q57174271 | The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation |
| Q35867975 | The influence of the young microbiome on inflammatory diseases--Lessons from animal studies |
| Q89152959 | The microbiome in autoimmune diseases |
| Q40084224 | Using murine colitis models to analyze probiotics-host interactions. |
Search more.